Evidence map›Paper›PMID 41091545›Full record

ArticleJournal of medical Internet research2025

Automated Speech Markers of Alzheimer Dementia: Test of Cross-Linguistic Generalizability.

Paula Andrea Pérez-Toro, Franco J Ferrante, Gonzalo Pérez, Boon Lead Tee, Jessica de Leon, Elmar Nöth, Maria Schuster, Andreas Maier, Andrea Slachevsky, Maria Luisa Gorno-Tempini and 3 more

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. The include network: Advancing cross-linguistic equity in brain health research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Benchmarking speech biomarkers of Alzheimer's against cognitive and neural measures.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Paula Andrea Pérez-ToroPattern Recognition Lab, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-2727-2116
Franco J FerranteCentro de Neurociencias Cognitivas, University of San Andrés, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0002-9455-2214
Gonzalo PérezCentro de Neurociencias Cognitivas, University of San Andrés, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0001-5781-8944
Boon Lead TeeGlobal Brain Health Institute, University of California, San Francisco, CA, United States.ORCID https://orcid.org/0000-0003-2217-3466
Jessica de LeonMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-9779-0541
Elmar NöthPattern Recognition Lab, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-3396-555X
Maria SchusterDepartment of Otorhinolaryngology, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID https://orcid.org/0000-0001-9122-7478
Andreas MaierPattern Recognition Lab, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-9550-5284
Andrea SlachevskyNeuropsychology and Clinical Neuroscience Laboratory (LANNEC), Faculty of Medicine, University of Chile, Santiago, Chile.ORCID https://orcid.org/0000-0001-6285-3189
Maria Luisa Gorno-TempiniMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-7426-7782
Agustín IbáñezCentro de Neurociencias Cognitivas, University of San Andrés, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0001-6758-5101
Juan Rafael Orozco-ArroyavePattern Recognition Lab, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-8507-0782
Adolfo GarcíaCentro de Neurociencias Cognitivas, University of San Andrés, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0002-6936-0114

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Augmenting Nurse Support and EHR Integration for the Pragmatic Trial of the UCSF-BHAU01NS128913 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine Laurel Possin · 2022 to 2026
$8.2M
An automated machine learning approach to language changes in Alzheimer’s disease and frontotemporal dementia across Latino and English-speaking populationsR01AG075775 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI, Adolfo Martin Garcia · 2023 to 2026
$7.2M
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1M
Chinese language versions of the National Alzheimer's Coordinating Center's Uniform Data Set version 4: a linguistic and cultural adaptation studyR01AG083840 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Clara Li, Boon Lead Tee · 2023 to 2026
$5.3M
The impact of bilingualism on cognitive reserve/resilience using socio-demographically and linguistically diverse populationsR01AG080469 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Suvarna Alladi, Ganesh M Babulal · 2023 to 2026
$4.0M
Word fluency task performance as a marker of Alzheimer’s disease in Tagalog/English bilingual speakerR01AG080396 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jessica Anne Deleon · 2023 to 2026
$3.3M
Circadian Disturbance and Dementia in Latin AmericaR01AG083799 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Kun Hu, Agustin M. Ibanez · 2023 to 2026
$3.0M
Novel Imaging and Biofluid Biomarkers of Small Vessel Cerebrovascular DiseaseUF1NS100608 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2021 to 2021
$2.5M
Primary Progressive Aphasia: Beyond the Clinical VariantsK23DC018021 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DELEON, JESSICA ANNE · 2020 to 2024
$995k
Chinese Language Assessment in Primary Progressive AphasiaR21AG068757 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GORNO TEMPINI, MARIA LUISA · 2021 to 2022
$360k
NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG057234NIA NIH HHS R01 AG075775NIA NIH HHS R01 AG080396NIA NIH HHS R01 AG080469NIA NIH HHS R01 AG083799NIA NIH HHS R01 AG083840NIA NIH HHS R21 AG068757NIDCD NIH HHS K23 DC018021NINDS NIH HHS U01 NS128913NINDS NIH HHS UF1 NS100608
6 · The paper itself

Abstract

backgroundAutomated speech and language analysis (ASLA) is gaining momentum as a noninvasive, affordable, and scalable approach for the early detection of Alzheimer disease (AD). Nevertheless, the literature presents 2 notable limitations. First, many studies use computationally derived features that lack clinical interpretability. Second, a significant proportion of ASLA studies have been conducted exclusively in English speakers. These shortcomings reduce the utility and generalizability of existing findings.

objectiveTo address these gaps, we investigated whether interpretable linguistic features can reliably identify AD both within and across language boundaries, focusing on English- and Spanish-speaking patients and healthy controls (HCs).

methodsWe analyzed speech recordings from 211 participants, encompassing 117 English speakers (58 patients with AD and 59 HCs) and 94 Spanish speakers (47 patients with AD and 47 HCs). Participants completed a validated picture description task from the Boston Diagnostic Aphasia Examination, eliciting natural speech under controlled conditions. Recordings were preprocessed and transcribed before extracting (1) speech timing features (eg, pause duration, speech segment ratios, and voice rate) and (2) lexico-semantic features (lexical category ratios, semantic granularity, and semantic variability). Machine learning classifiers were trained with data from English-speaking patients and HCs, and then tested (1) in a within-language setting (with English-speaking patients and HCs) and (2) in a between-language setting (with Spanish-speaking patients and HCs). Additionally, the features were used to predict cognitive functioning as measured by the Mini-Mental State Examination (MMSE).

resultsIn the within-language condition, combined speech timing and lexico-semantic features yielded maximal classification (area under the receiver operating characteristic curve [AUC]=0.88), outperforming single-feature models (AUC=0.79 for timing features; AUC=0.80 for lexico-semantic features). Timing features showed the strongest MMSE prediction (R=0.43, P<.001). In the between-language condition, speech timing features generalized well to Spanish speakers (AUC=0.75) and predicted Spanish-speaking patients' MMSE scores (R=0.39, P<.001). Lexico-semantic features showed lower performance (AUC=0.64) and no significant MMSE prediction (R=-0.31, P=.05). The combined model did not improve results (AUC=0.65; R=0.04, P=.79).

conclusionsThese results suggest that while both timing and lexico-semantic features are informative within the same language, only speech timing features demonstrate consistent performance across languages. By focusing on clinically interpretable features, this approach supports the development of clinically usable ASLA tools.

Indexed as

Alzheimer DiseaseLinguisticsSpeechAgedAged, 80 and overFemaleHumansLanguageMaleMiddle AgedAlzheimer diseaseautomated speech and language analysiscross-linguistic validitydigital biomarkersinterpretability

Identifiers

PMID41091545
PMCPMC12572752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.